NovoCure Ltd
For the period ended Jun 30, 2024. Filed Jul 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Jul 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Securities Trading Plans of Executive Officers and Directors
Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables prearranged transactions in securities in a manner that avoids concerns about initiating transactions at a future date while possibly in possession of material nonpublic information. Our Insider Trading Policy permits our executive officers and directors to enter into trading plans designed to comply with Rule 10b5-1.
During the three-month period ending June 30, 2024, we did notadopt orterminate any contract, instruction or written plan for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
The following table describes contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended (each a "Rule 10b5-1 Plan") adopted by our executive officers and directors during the three month period ending June 30, 2024:
| Name | Title | Date of Adoption | Duration of Rule 10b5-1 Plan | Aggregate Number of Securities to be Purchased Pursuant to the Rule 10b5-1 Plan | Aggregate Number of Securities to be Sold Pursuant to the Rule 10b5-1 Plan |
|---|---|---|---|---|---|
| Uri Weinberg | Chief Innovation Officer | June 5, 2024 | September 4, 2024 - December 31, 2026 | — | 278,612 |
| Wilhelmus Groenhuysen (1) | Chief Operating Officer | June 5, 2024 | September 4, 2024 - May 31, 2025 | — | 1,249,563 |
| Gabriel Kinyip Leung | Director | June 5, 2024 | September 4, 2024 - August 31, 2025 | — | 88,413 |
(1) Includes shares held by the Groenhuysen Family Trust, in which Mr. Groenhuysen maintains a pecuniary interest. Mr. Groenhuysen does not disclaim beneficial ownership of such shares.
During the three-month period ending June 30, 2024, none of our executive officers or directors terminated a Rule 10b5-1 trading plan oradopted orterminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.